Global Adult Malignant Glioma Therapeutics Market Growth Analysis 2024 – Forecast Market Size And Key Factors Driving Growth

An adult malignant glioma is a type of brain tumor that originates in the glial cells of the brain or spinal cord. Adult malignant glioma therapeutics refers to the various treatment options available for malignant gliomas in adults, aiming to improve quality of life and prolong survival.

Sizing and Forecast
The adult malignant glioma therapeutics market size has grown rapidly in recent years. It will grow from $2.03 billion in 2023 to $2.25 billion in 2024 at a compound annual growth rate (CAGR) of 10.5%.  The  growth in the historic period can be attributed to increased incidence rates, patient advocacy initiatives, personalized medicine approaches..

The adult malignant glioma therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.23 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%.  The growth in the forecast period can be attributed to immunotherapy advancements, targeted therapies, biomarker discoveries, liquid biopsy applications, expanded access programs.. Major trends in the forecast period include patient-centric drug development, fast-track and breakthrough designation, advances in drug delivery systems, collaborative research initiative, integration of artificial intelligence..

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Segmentation & Regional Insights
The adult malignant glioma therapeutics market covered in this report is segmented –
1) By Type Of Disease: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Other Types
2) By Therapy: Chemotherapy, Targeted Therapy, Radiotherapy, Other Therapies
3) By End-User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers, Other End Users

North America was the largest region in the adult malignant glioma therapeutics market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adult malignant glioma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13178&type=smp

Major Driver Impacting Market Growth
The growing cases of brain tumors are expected to drive the adult malignant glioma therapeutics market growth. A brain tumor is an abnormal mass of tissue in which the normal systems that regulate cells appear not to affect the uncontrollable growth and multiplication of the cells. Adult malignant glioma is a type of brain tumor made up of cells that grow abnormally and uncontrollably. Adult malignant glioma treatment treats brain tumors by combining surgery, radiation therapy, and chemotherapy. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of brain and nervous system cancer cases increased to 24,810 in 2023, reflecting a growth of 3.85% from 23,890 in 2020. Therefore, the growing cases of brain tumors are driving the adult malignant glioma therapeutics market.

Key Industry Players
Major companies operating in the adult malignant glioma therapeutics market report are Johnson & Johnson Private Limited, Pfizer Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Allergan plc, AbbVie Inc., Novartis AG, Bayer AG, Merck & Co Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Abbott Laboratories, AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., GT Medical Technologies Inc., Lupin Limited, Mylan NV, Sanofi SA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Genetech Inc., Amneal Pharmaceuticals LLC, Emcure Pharmaceuticals Limited, Novocure Ltd., Arbour Pharmaceuticals LLC, Basilea Pharmaceuticals Ltd.

The adult malignant glioma therapeutics market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis

Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model